ISRCTN50181543已完成不适用
Phase II trial: Pre-operative, long-term chemoradiation with capecitabine, oxaliplatin and bevacizumab in locally advanced rectal cancer
niversity Medical Centre Schleswig-Holstein (Universitätsklinikum Schleswig-Holstein) (Germany)0 个研究点目标入组 68 人开始时间: 2008年5月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age >18 years, both males and females
- •2. Patients with histologically proven adenocarcinoma of the rectum, tumour = 16 cm from the anal verge, u T3-4 or uN+ or Mason III/IV, staging will must be done by endorectal ultrasound and magnetic resonance imaging (MRI) or by endorectal unltrasound and high resolution computed tomography, no evidence of metastatic disease
- •3. No prior treatment, except for ileostomy (if necessary due to ileus)
- •4. No fistulas near the tumour
- •5. Eastern Cooperative Oncology Group (ECOG) Performance Status <= 1
- •6. Adequate bone marrow, hepatic and renal function:
- •6.1. Haemoglobin >10.0 g/dL, leucocyte count > 3.5 x 109/L, absolute neutrophil count >1.5 x 109/L, platelet count >100 x 109/L
- •6.2. Alkaline phosphatase, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) <3 x upper limit of normal (ULN)
- •6.3. Total bilirubin <= 2 mg/dL
- •6.4. Creatinine clearance >50 mL/min
- •6.5. Creatinine <= 1.5 x ULN
- •7. Patients must have understood the contents of the protocol and signed written informed consent
排除标准
- •1. No presence of adequate contraception in fertile patients
- •2. Pregnant or breastfeeding women
- •3. Previous or persistent alcohol or drug abuses
- •4. Prior radiotherapy or chemotherapy to the pelvis, for any reason
- •5. Treatment with any investigational drug, agent nor procedure, (i.e. did not participate in another trial) within 4 weeks before entry in this trial
- •6. Treatment with other anti-cancer agents
- •7. Patients not able or willing to comply with the protocol treatment and investigations
- •8. Patients with uncontrolled severe somatic or psychological diseases, e.g.:
- •8.1. Despite medication uncontrolled cardiac diseases, myocardial infarction within the last 6 months prior to enrolment
- •8.2. Neurological or psychiatric disorders including seizures and dementia
- •8.3. Active, uncontrolled infection and sepsis
- •9. Symptomatic peripheral neuropathy >= grade 2 (National Cancer Institute - Common Terminology Criteria for Adverse Events [NCI CTCAE])
- •10. Concurrent malignancies, with the exception of successfully treated cone-biopsied in situ carcinoma of the cervix or basal cell carcinoma of the skin
- •11. Chronic diarrhoea > grade 1 (NCI CTCAE)
- •12. Chronic inflammatory bowel disease or other pre-existing condition which would deter resorption of drugs (e.g. dumping syndrome, evidence of accelerated small bowel passage, evidence of deterred resorption due to gastric or bowel surgery)
- •13. Known hypersensitivity to platinum-containing drugs
- •14. Concurrent use of the antiviral agent sorivudine or chemically related analogues
- •15. Known dihydropyrimidine dehydrogenase deficiency
- •16. Known allergy to any of the study drugs or its ingredients
- •17. Interstitial pneumonia or extensive, symptomatic lung fibrosis
- •18. Organ allograft requiring immunosuppressive therapy
- •19. Severe, non-healing wounds, ulcers or fractures
- •20. Thrombosis or severe bleeding (except for bleeding of the tumour) within 6 months prior to enrolment
- •21. Bleeding diathesis or thrombophilia
- •22. Therapeutic anticoagulation (with marcumar or heparin)
- •23. Acetylsalicylic acid >325 mg per day or routine use of non-steroidal anti-inflammatory drugs which inhibit the function of platelets
- •24. Ascites nescessitating puncture
- •25. Patients with proteinuria >= 1+ at baseline, as long as a 24?hour urine collection demonstrates >500 mg of protein/ 24 hr
- •26. Concurrent treatment with St. John's wort
- •27. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the preoperative chemoradiation (exceptions: protective ileostomy and the planned resection of the rectal cancer)
研究者
相似试验
招募中
不适用
A phase 2 clinical trial of preoperative chemoradiation therapy for locally advanced low rectal cancer with limited radiation field to the lesser pelvisocally advanced low rectal cancerJPRN-UMIN000013383Gunma University Graduate School of Medicine52
已完成
2 期
Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IIIA Non-Squamous Non-Small Cell Lung Canceron-squamous, Non-small cell lung cancerJPRN-UMIN000004487Osaka International Cancer Institute30
已完成
不适用
A Phase II trial of preoperative chemoradiation therapy with S-1 for locally-advanced rectal cancerlocally advanced rectal cancer (T3-4, N0-2, M0)JPRN-UMIN000015530Department of Surgery, Miyagi Cancer Center15
已完成
不适用
A phase II study of preoperative chemotherapy cosisting docetaxel, oxaliplatin and S-1 for the clinical Stage III gastric cancerGastric cancerJPRN-UMIN000017652Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine50
终止
2 期
Neo-Adjuvant FOLFOX for Rectal CarcinomaRectal NeoplasmsNCT00832299Beth Israel Medical Center2